Biotech Press Releases

A3 Analytics, the AI-native operational intelligence company for automated and self-driving laboratories, today announced that Greg Snyder, PhD, has joined the company as Co-Founder and Chief Operating Officer.

With $NTRB shares gaining significant momentum in September, investors are watching a rapidly approaching warrant expiration, new intellectual-property progress for Nutriband's abuse-deterrent fentanyl platform, strengthening visibility through Nasdaq's..

With a potential Q4 commercial launch, expanding diagnostic opportunities, a major telehealth platform, veterinary oncology initiatives and a proposed Xycota acquisition, NexTel is positioning $MAJI around multiple potential growth catalysts

Today's GeNeuro patent milestone adds a potentially significant ALS opportunity to an already expanding NRx platform, while HOPE Therapeutics advances robotic TMS deployment and the company's preservative-free ketamine program moves closer to...

NRx's HOPE Therapeutics is preparing to deploy Zeta Surgical's newly FDA-cleared robotic TMS technology in Florida, adding another major piece to a rapidly expanding neuropsychiatric platform while the company advances toward potential 2026...

With revenue shifting rapidly beyond China, positive net income returning, new international registrations, an expanding U.S.

Q2 update reinforces the central NRXP investment thesis: preservative-free ketamine is moving toward commercialization while NRX-101, DARPA funding, HOPE Therapeutics and a stronger balance sheet create multiple potential catalysts.

First-cycle FDA review delivers one of the strongest signals yet that NRx's preservative-free ketamine opportunity may be entering its final stretch, while the company's broader neuropsychiatric pipeline continues to gain momentum.

Potential DARPA Award, FDA-Authorized Phase 2/3 Trial, Breakthrough Therapy NRX-101, and Robotic-Enabled TMS Platform Highlight Expanding Opportunities for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)

First Commercial Deployment of FDA-Cleared AI-Guided TMS Navigation System, Expanded FDA Pathway for NRX-101, and Growing Commercial Infrastructure Highlight Accelerating Momentum for NRx Pharmaceuticals (N A S D A Q: NRXP)

A3 Analytics, the AI-native operational intelligence company for automated and self-driving laboratories, today announced that Greg Snyder, PhD, has joined the company as Co-Founder and Chief Operating Officer.

With $NTRB shares gaining significant momentum in September, investors are watching a rapidly approaching warrant expiration, new intellectual-property progress for Nutriband's abuse-deterrent fentanyl platform, strengthening visibility through Nasdaq's..

With a potential Q4 commercial launch, expanding diagnostic opportunities, a major telehealth platform, veterinary oncology initiatives and a proposed Xycota acquisition, NexTel is positioning $MAJI around multiple potential growth catalysts

Today's GeNeuro patent milestone adds a potentially significant ALS opportunity to an already expanding NRx platform, while HOPE Therapeutics advances robotic TMS deployment and the company's preservative-free ketamine program moves closer to...

NRx's HOPE Therapeutics is preparing to deploy Zeta Surgical's newly FDA-cleared robotic TMS technology in Florida, adding another major piece to a rapidly expanding neuropsychiatric platform while the company advances toward potential 2026...

With revenue shifting rapidly beyond China, positive net income returning, new international registrations, an expanding U.S.

Q2 update reinforces the central NRXP investment thesis: preservative-free ketamine is moving toward commercialization while NRX-101, DARPA funding, HOPE Therapeutics and a stronger balance sheet create multiple potential catalysts.

First-cycle FDA review delivers one of the strongest signals yet that NRx's preservative-free ketamine opportunity may be entering its final stretch, while the company's broader neuropsychiatric pipeline continues to gain momentum.

Potential DARPA Award, FDA-Authorized Phase 2/3 Trial, Breakthrough Therapy NRX-101, and Robotic-Enabled TMS Platform Highlight Expanding Opportunities for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)

Industry Leaders Identify Operational Excellence, Revenue Leadership, and Strategic Collaboration as the Future of Scalable Enterprise

First Commercial Deployment of FDA-Cleared AI-Guided TMS Navigation System, Expanded FDA Pathway for NRX-101, and Growing Commercial Infrastructure Highlight Accelerating Momentum for NRx Pharmaceuticals (N A S D A Q: NRXP)

Cosmos Health Inc. (N A S D A Q: COSM): 18 Series Nutraceutical Expansion, Record Q1 Results, EIB Financing Initiative, AI-Powered Drug Development, And Strong Long-Term Financial Guidance Position Cosmos Health For Potential Multi-Year Expansion

Cosmos Health Inc. (N A S D A Q: COSM): Veterinary Expansion, Proprietary Healthcare Brands, AI-Powered Drug Development, Telehealth Growth, and Strong Financial Guidance Position Cosmos Health for Potential Multi-Year Expansion

Expanding HOPE Therapeutics Network Positions NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP for Potential Breakout 2026 Growth

NRx Pharmaceuticals, Inc.Improved Financial Position, Commercial Ketamine Manufacturing, FDA Progress, and Expanding Neuroplastic Therapy Infrastructure Position $NRXP for a Potential Breakout Phase

Commercial-Ready Ketamine Production, FDA Alignment, and Expanding AI Neurotherapy Platform Position $NRXP at the Center of a Multi-Billion-Dollar Mental Health Transformation

NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP: Dual FDA Pathways, and an Expanding AI-Driven Treatment Ecosystem Position NRXP at the Forefront of a Multi-Billion-Dollar Mental Health Transformation

Proprietary Stem Cell Platform Meets Institutional-Grade AI Infrastructure—Positioning $KALA at the Center of a Massive, Underserved $167B R&D Opportunity

Breakthrough Regulatory Alignment Now Meets Cutting-Edge Robotic Brain Therapy—Positioning $NRXP at the Intersection of Pharma, AI, and National Defense

Positive Phase II Results, Ongoing Phase III Trial, and Cash Runway Into Late-2027 Positions Cardiol Therapeutics Inc. (N A S D A Q: CRDL) $CRDL for Transformational Growth

Secure, on-premises AI infrastructure, recurring revenue model, and entry into a $167B+ R&D ecosystem position $KALA at the forefront of the agentic AI healthcare revolution

NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP Has a One-Day Depression Treatment, AI Monitoring Breakthrough, and Potential 2026 Drug Approval Put $NRXP in a Category of Its Own

Philanthropic venture fund supports next generation of startups to expand opportunity and economic growth for future generations

Accelerating scalable AI infrastructure, secures up to $9.75M financing, and advances FDA-registered diagnostic technology alongside next-generation generative AI platforms $ALBT

87% Clinical Response From Non-Invasive Neuroplastic Therapy Positions $NRXP at the Forefront of Next-Generation Mental Health Treatment. NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)

TAEUS® Technology Delivers MRI-Level Liver Fat Measurement at the Point of Care for Disease Affecting 30% of Adults Worldwide: $NDRA

KALA BIO, Inc. (N A S D A Q: KALA) $KALA Targets Massive AI Opportunity in Biotech with Secure On-Premises Infrastructure Platform

Green Seal-Certified. Hospital-Grade Disinfection Meets Explosive Omni-Channel Growth Strategy Including pet-care, and biosafety sectors.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP: FDA Alignment, 70,000-Patient Real-World Data, and a Debt-Free Balance Sheet Position NRXP for Transformational 2026 Catalysts

Company focuses on compliant, research-use-only biotech compounds for laboratory clients

Collaboration Carried Out With Support from Brain Research UK